◎Daikenchuto raises plasma levels of motilin in cancer patients with morphine-induced constipation. Sato Y, Itoh H, Takeyama M. J. Trad. Med., 26(3), 122-130 (2010)

◎がん化学療法におけるレジメン登録制の構築とレジメンオーダシステム導入の評価　佐藤雄己, 安部智英，鈴木陽介，西村文宏，半田有希子，河島史絵，伊東弘樹，大津智，白尾國昭，武山正治，日本病院薬剤師会誌, 46(3), 373-377 (2010)

◎SSRISによるセロトニン症候群と退薬症候群　寺尾　岳　亀井公恵　片山陽介,　精神科治療学, 25, 326-329 (2010)

◎血清アルブミン値と年齢との関連性の検討～急性期病院における調査から～ 北英士，伊東弘樹，染矢浩美，平島智子，野田武，井上真，石松裕和，阿部浩子 静脈経腸栄養 25(6) 63-70 (2010)

◎Sodium alginate as an ideal submucosal injection material for endoscopic submucosal resection: preliminary experimental and clinical study. Akagi T, Yasuda K, Tajima M, Suzuki K, Inomata M, Shiraishi N, Sato Y, Kitano S. Gastrointest Endosc. 74(5), 1026-32 (2011)

◎No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy. Suzuki Y., Itoh H., Abe T., Nishimura F., Sato Y., Takeyama M., J. Pharm. Pharmacol., 63, 976-981 (2011)

◎Comparison of the effects of pantethine and fursultiamine on plasma gastrointestinal peptide levels in healthy volunteers. Suzuki Y., Itoh H., Abe T., Nishimura F., Sato Y., Takeyama M., Biol. Pharm. Bull., 34, 1640-1643 (2011)

◎Mirtazapine suppresses the increases in plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure. Suzuki Y., Itoh H., Abe T., Tatsuta R., Sato Y., Takeyama M., Biomedicine & Aging Pathology, 2, 1-5 (2012)

◎ Comparison of the effects of pantethine and fursultiamine on plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure. Itoh H., Suzuki Y., Yamamura R., Tatsuta R., Sato Y., Takeyama M., Biomedicine & Aging Pathology, 2, 41-44 (2012)

◎ Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy. Itoh H., Suzuki Y., Fujisaki K., Sato Y., Takeyama M., Biol. Pharm. Bull., 35, 971-974 (2012)

◎ Significant increase in salivary substance P level after a single oral dose of Japanese herbal medicine Dai-kenchu-to in humans. Suzuki Y., Itoh H., Yamamura R., Tatsuta R., Sato Y., Takeyama M., Biomedicine & Aging Pathology, 2, 81-84 (2012)

◎Establishment and clinical application of a highly sensitive enzyme immunoassay for determination of N-acetyl-seryl-aspartyl-lysyl-proline. Suzuki Y., Itoh H., Katagiri F., Sato F., Kawasaki K., Sato Y., Mimata H., Takeyama M., J. Pept. Sci., 18, 276-281 (2012)

◎Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia. Suzuki Y., Kawasaki K., Sato Y., Tokimatsu I., Itoh H., Hiramatsu K., Takeyama M., Kadota JI., Chemotherapy, 58, 308-312 (2012)

◎処方オーダリングシステムを利用した持参薬チェックシステムの構築と評価　大塚昌代，山村亮太，西村文宏，伊東弘樹，武山 正治 日本病院薬剤師会雑誌48（4）435-439 (2012)

◎インシデント防止を目的とした注射薬取り揃えシステムの開発 西村文宏, 伊東弘樹, 中原良介, 佐藤雄己, 武山正治 日本病院薬剤師会雑誌48（10）1226-1229(2012)

◎PDAを用いた計数調剤管理システムによる調剤過誤防止と管理台帳の電子化 山村亮太，伊東弘樹，西村文宏，因泥栄一郎，武山正治 日本病院薬剤師会雑誌48（9）1107-1111 (2012)

◎Effect of pilocarpine on substance P and calcitonin gene-related peptide releases correlate with salivary secretion in human saliva and plasma. Sato Y, Itoh H, Suzuki Y, Tatsuta R, Takeyama M. J Clin Pharm Ther, 38, 19-23 (2013)

◎Interaction between Pirenzepine and Ninjinto, a Traditional Japanese Herbal Medicine, on the Plasma Gut-Regulated Peptide Levels in Humans, Sato Y, Itoh H, Suzuki Y, Tatsuta R, Takeyama M, Int J Pept, 2013, 5 (2013)

◎Development and clinical application of an enzyme immunoassay for the determination of midregional proadrenomedullin. Suzuki Y., Itoh H., Katagiri F., Sato F., Sato Y., Kawasaki K., Sato Y., Mimata H., Takeyama M., J. Pept. Sci., 19, 59-63 (2013)

◎ Significant decrease in plasma midregional proadrenomedullin level in patients with end-stage renal disease after living kidney transplantation. Suzuki Y., Itoh H., Katagiri F., Sato F., Kawasaki K., Sato Y., Sato Y., Mimata H., Takeyama M., Peptides, 43, 102-104 (2013)

◎ Significant Increase in Salivary Substance P Level after a Single Oral Dose of Cevimeline in Humans. Suzuki Y., Itoh H., Amada K., Yamamura R., Sato Y., Takeyama M., Int. J. Pept., 2013, 284765 (2013)

◎Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Suzuki Y., Tokimatsu I., Sato Y., Kawasaki K., Sato Y., Goto T., Hashinaga K., Itoh H., Hiramatsu K., Kadota JI., Clin. Chim. Acta., 424, 119-122 (2013)

◎Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. Suzuki Y., Itoh H., Sato F., Kawasaki K., Sato Y., Fujioka T., Sato Y., Ohno K., Mimata H., Kishino S., J. Lipid Res., 54, 2568-2572 (2013)

◎Relationship between plasma mid-regional pro-adrenomedullin level and resistance to antihypertensive therapy in stable kidney transplant recipients. Suzuki Y., Itoh H., Katagiri F., Sato F., Kawasaki K., Sato Y., Sato Y., Mimata H., Takeyama M., Peptides, 48, 45-48 (2013)

◎業務効率化を目的とした手術室セット　薬品管理システムの開発 西村 文宏, 藤崎 佳那子, 龍田 涼佑, 槇原 洋子, 佐藤 雄己, 伊東 弘樹 日本病院薬剤師会雑誌49（7）737-741(2013)

◎Affective temperaments and psychotropic adherence. Kamei K., Terao T., Katayama Y., Hoaki N., J Affect Disord, 150（3）1142-1147(2013)

◎Association of Plasma Concentration of 4β-Hydroxycholesterol with CYP3A5 Polymorphism and Plasma Concentration of Indoxyl Sulfate in Stable Kidney Transplant Recipients. Suzuki Y., Itoh H., Fujioka T., Sato F., Kawasaki K., Sato Y., Sato Y., Ohno K., Mimata H., Kishino S., Drug Metab. Dispos., 42, 105-110 (2014)

◎Significant Decrease in Plasma N-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation. Suzuki Y., Katagiri F., Sato F., Fujioka K., Sato Y., Fujioka T., Sato Y., Mimata H., Itoh H., Biol. Pharm. Bull., 37(6), 1075-1079 (2014).

◎Therapeutic Window of Lamotrigine for Mood Disorders: A Naturalistic Retrospective Study. Kayamaya Y, Terao K, Kamei K, Hatano K, Kohno K, Makino M, Mizokami Y, Kodama K, Itoh H, Pharmacopsychiatry, 47, 111-114 (2014) 　　　　　

◎Darbepoetin Alfa Increases Plasma N-acetyl-seryl-aspartyl-lysyl-proline Level in Kidney Transplant Recipient: A Case Report. Suzuki Y., Katagiri F., Sato F., Sato Y., Mimata H., Itoh H., J.Transplant.Technol.Res., 4, 1-3 (2014)

◎ドセタキセル水和物の先発医薬品から後発医薬品への切り替えにおける安全性の比較検討 中原良介, 佐藤雄己, 伊東健太郎, 伊東弘樹 日本病院薬剤師会雑誌 51（2）220-224(2015)

◎A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Suzuki Y., Tokimatsu I., Morinaga Y., Sato Y., Takano K., Kohno K., Ogata M., Hiramatsu K., Itoh H., Kadota JI., Clin. Chim. Acta., 440, 183-187 (2015)

◎外来化学療法室における薬剤師の薬学的ケアの実施とそのアウトカムの評価 龍田涼佑, 佐藤雄己, 伊東弘樹 日本病院薬剤師会雑誌 51（5）557-561(2015)

◎Significance of high trough concentration of teicoplanin in the treatment of methicillin-resistant Staphylococcus aureus infection. Sato Y., Tokimatsu I.,Suzuki Y.,Itoh H.,Hiramatsu K., Kadota JI., Chemotherapy.,60, 274-278 (2015)

◎成人血液悪性腫瘍患者におけるラスブリカーゼ投与後の尿酸値上昇のリスク因子　佐藤雄己，津田浩和，龍田涼佑，伊東弘樹 医療薬学　41（8）585-593(2015)

◎急性リチウム中毒の10症例の検討　遠山泰崇，佐藤雄己，鈴木陽介，田辺三思，竹中隆一，和田伸介，石井圭亮，伊東弘樹 医療薬学　41（8）594-599(2015)

◎CYP3A5 polymorphism affects the increase in CYP 3A activity after living kidney trasplantation in patients with end stage renal disease, Suzuki Y., Fujioka T., Sato F., Matsumoto K, Muraya N., Tanaka R., Sato Y., Ohno K., Mimata H., Kishino S., Itoh H. Br.J.Clin.Pharm. 80(6),1421-1428 (2015)

◎Effect of goshajinkigan, a Japanese herbal medicine, on the plasma neuropeptides in humans. Sato Y, Tatsuta R, Suzuki Y, Itoh H, Clinical Research and Trial. 1(2), 34-37 (2015)

◎アラート機能活用および採用規格見直しによるゾルピデム適正使用への取り組み 山村亮太, 佐藤雄己, 中原良介, 伊東弘樹 日本病院薬剤師会雑誌 51（12）1445-1448 (2015)

◎Association of metabolic complications with plasma mid-regional pro-adrenomedullin level in stable kidney transplant recipients. Suzuki Y, Katagiri F, Sato F, Fujioka T, Tanaka R, Sato Y, Mimata H, Itoh H., Clin. Chim. Acta., 453, 160-163 (2015)　　　　

◎Performance characteristics between TDxRFLx and TBA-25FR for the therapeutic drug monitoring of methotrexate. Kaneko T, Fujioka T, Suzuki Y, Sato Y, Itoh H, J Pharm Health Care Sci. 8, 2-7 (2016)

◎パクリタキセルの後発医薬品間の製剤学的特性および治療学的安全性の比較.小野寛之，佐藤雄己，大山展弘，中原良介，倉成正恵，伊東弘樹, 日本医薬品情報学会誌. 18(1), 7-11 (2016)

◎High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in human plasma from patients with chronic myelogenous leukemia, and comparison with liquid chromatography-tndem mass spectrometry. Nakahara R, Sato Y, Itoh H, J Clin Lab Anal. 30(6),1028-1030 (2016).

◎Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. Witt L, Suzuki Y, Hohmann N, Mikus G, Haefeli WE, Burhenne J. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1027,207-213 (2016)

◎救急領域における薬剤師によるTDM検査オーダ入力支援の有用性 佐藤雄己，内匠幸恵，金子哲也，田中遼大 ，藤岡孝志 , 伊東弘樹, 日本医事新報. 4828,40-45 (2016)

◎Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy. Goto K, Sato Y, Yasuda N, Hidaka S,Suzuki Y, Tanaka R, Kaneko T, Nonoshita K, Itoh H, J Basic Clin Physiol Pharmacol. 27(6), 625-631(2016)

◎Clinical implications of plasma N-acetyl-seryl-aspartyl-lysyl-proline level in stable kidney transplant recipients Suzuki Y, Katagiri F, Sato F, Fujioka K, Sato Y, Fujioka T, Sato Y, Mimata H, Itoh H. Clin Lab, 62, 1323-1328 (2016)

◎オキサリプラチンの先発医薬品と後発医薬品の治療学的安全性の比較, 佐藤雄己，大山展弘，小野寛之，天田耕平，中原良介，伊東弘樹，診療と新薬. 53(10), 44-48 (2016)

◎A retrospective analysis of risk factors for linezolid-associated hyponatremia in Japanese patients.Tanaka R,Suzuki Y,Takumi Y,Iwao M,Sato Y,Hashinaga K,Hiramatsu K,Kadota JI, Itoh H. Biol.Pharm.Bull, 39(12),1968-1973(2016)

◎認知症外来患者に対する薬学的ケアの有用性 佐藤雄己, 吉岩あおい，龍田涼佑，山本恭子，宮﨑英士，伊東弘樹, 医療薬学. 42(11),767-772 (2016)

◎糖尿病患者における医薬品の服用に関する意識調査 佐藤雄己，天田耕平，中原良介，小野優子，内匠幸恵，後藤伴美，月森由紀，森永裕子，膳所祐穂，岡部耕平，田名網悠，伊東弘樹 くすりと糖尿病学会誌 6(1), 81-87（2017）

◎ゲムシタビンの後発医薬品間の調製効率および治療学的安全性の比較　佐藤雄己，小野寛之，天田耕平，中原良介，伊東弘樹, 癌と化学療法, 44(4), 319-323(2017)

◎ Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Suzuki Y, Witt L, Mier W, Mikus G, Markert C, Haefeli WE, Burhenne J. J Pharm Biomed Anal, 142,84-90 (2017)

◎Pharmacokinetic/pharmacodynamic analysis for doripenem regimens in intensive care unit patient. Tanaka R, Sato Y, Goto K, Yasuda N, Ohchi Y, Suzuki Y, Ito K, Kaneko T, Nonoshita K, Itoh H. Biol Pharm Bull,40(8),1226-1231 (2017)

◎外来化学療法室における薬剤師によるレジメンオーダ入力支援の有用性の検討 龍田涼佑, 中原良介，佐藤雄己, 伊東弘樹 日本病院薬剤師会雑誌 53(5): 541 -546 (2017)

◎Sensitive and selective quantification of total and free itraconazole and hydroxyitraconazole in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Suzuki Y, Tanaka R, Oyama N, Nonoshita K, Hashinaga K, Umeki K, Sato Y, Hiramatsu K, Kadota JI, Itoh H. Clin Biochem, 50(18),1228-1236 (2017)

◎ A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection. Sumimoto T, Nakahara R, Sato Y, Itoh H, J Clin Lab Anal. 32, 1-3 (2018)

◎Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy. Sato Y, Hiramatsu K, Suzuki Y,Tanaka R, Kaneko T, Nonoshita K, Ogata M, Kadota JI, Itoh H. Chemotherapy. 63(1),29-34(2018)

◎Comparison of whole blood tacrolimus concentrations measured by different immunoassay systems Kaneko T, Fujioka T, Suzuki Y, Nagano T, Sato Y Itoh H, J Clin Lab Anal. 32, e22587(2018)

◎Filgrastim biosimilar for neutropenia in gynecological cancer patients receiving chemotherapy: a prospective, single-center, non-randomized, open trial. Sato Y, Sumimoto T, Tsushita H, Nakahara R, Matsumoto H, Itoh H, Pharmazie. 8, 486-488(2018)

◎糖尿病患者における配合剤に関する意識調査 亀井進太郎，佐藤雄己，炭本隆宏，津下遥香，田中遼大，伊東弘樹，診療と新薬，55, 862-867 (2018)

◎Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Tanaka R, Yasuda N, Kai S, Kitano T, Suzuki Y, Sato Y, Koga H, Goto K, Ohchi Y, Itoh H, J Pharm Biomed Anal, 165, 56-64 (2019)

◎Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients. Suzuki Y, Muraya N, Fujioka T, Sato F, Tanaka R, Matsumoto K, Sato Y, Ohno K, Mimata H, Kishino S, Itoh H. Pharmacol Rep, 71, 276-281 (2019)

◎Recovery of OATP1B Activity after Living Kidney Transplantation in Patients with End-Stage Renal Disease. Suzuki Y, Ono H, Tanaka R, Sato F, Sato Y, Ohno K, Mimata H, Itoh H. Pharm Res, 36(4),59 (2019)

◎High-sensitivity simultaneous quantification of tacrolimus and 13-O-demethyl tacrolimus in human whole blood using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Ono H, Suzuki Y, Kaneko T, Tanaka R, Sato F, Sato Y, Mimata H, Itoh H. Biomed Chromatogr, 33(9), e4584 (2019)

◎Comparison of performance characteristics between high-performance liquid chromatography and latex agglutination turbidimetric immunoassay for therapeutic drug monitoring of zonisamide. Eto D, Tanaka R, Suzuki Y, Sato Y, Itoh H. J Clin Lab Anal. 33(7), e22940 (2019)

◎Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report. Nakahara R, Sumimoto T, Ogata M, Sato Y, Itoh H. Clin Case Rep. 7(7), 1419-1421 (2019)

◎不眠症治療薬の種類および服用量と転倒率との関連性　佐藤雄己，龍田涼佑，中原良介，田中遼大，津下遥香，炭本隆宏，伊東弘樹　診療と新薬，56(8), 576-581 (2019)